TY - JOUR
T1 - Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
AU - Einama, T.
AU - Homma, S.
AU - Kamachi, H.
AU - Kawamata, F.
AU - Takahashi, K.
AU - Takahashi, N.
AU - Taniguchi, M.
AU - Kamiyama, T.
AU - Furukawa, H.
AU - Matsuno, Y.
AU - Tanaka, S.
AU - Nishihara, H.
AU - Taketomi, A.
AU - Todo, S.
N1 - Funding Information:
This work was supported in part by a grant-in-aid from the foundation for the Department of General Surgery, Hokkaido University Alumni Association.
PY - 2012/6/26
Y1 - 2012/6/26
N2 - Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.
AB - Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.
KW - Mesothelin
KW - gastric cancer
KW - luminal membrane expression
UR - http://www.scopus.com/inward/record.url?scp=84863006209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863006209&partnerID=8YFLogxK
U2 - 10.1038/bjc.2012.235
DO - 10.1038/bjc.2012.235
M3 - Article
C2 - 22644300
AN - SCOPUS:84863006209
SN - 0007-0920
VL - 107
SP - 137
EP - 142
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -
